PCSA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of -255.85%. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 753.24%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -85.52%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.128, which suggesting that the stock is 12.829% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus 11.41x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of --. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Palatin Technologies's return on equity of --.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 753.24%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Processa Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Processa Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.128, which suggesting that the stock is 12.829% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Palatin Technologies's net income of --. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of -650.85%. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 753.24%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.18 which suggests that it could grow by 523.91%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Pyxis Oncology, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Pyxis Oncology, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.128, which suggesting that the stock is 12.829% more volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pyxis Oncology, Inc. quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus 24.99x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of --. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 753.24%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2613.18%. Given that Theriva Biologics, Inc. has higher upside potential than Processa Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Processa Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.128, which suggesting that the stock is 12.829% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.